Publication: Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Lanctôt, K. L., J. Amatniek, S. Ancoli-Israel, S. E. Arnold, C. Ballard, J. Cohen-Mansfield, Z. Ismail, et al. 2017. “Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.” Alzheimer's & Dementia : Translational Research & Clinical Interventions 3 (3): 440-449. doi:10.1016/j.trci.2017.07.001. http://dx.doi.org/10.1016/j.trci.2017.07.001.
Research Data
Abstract
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under-recognized and often challenging to treat. With this in mind, the Alzheimer's Association convened a Research Roundtable in May 2016, bringing together experts from academia, industry, and regulatory agencies to discuss the latest understanding of NPSs and review the development of therapeutics and biomarkers of NPSs in AD. This review will explore the neurobiology of NPSs in AD and specific symptoms common in AD such as psychosis, agitation, apathy, depression, and sleep disturbances. In addition, clinical trial designs for NPSs in AD and regulatory considerations will be discussed.
Description
Other Available Sources
Keywords
Alzheimer's disease, Neuropsychiatric symptoms, Trial design, Delusions, Hallucinations, Agitation, Apathy, Depression, Sleep disturbance
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service